<DOC>
	<DOCNO>NCT00003998</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . It yet know combination chemotherapy regimen effective treat ovarian epithelial cancer . PURPOSE : Randomized phase III trial compare effectiveness carboplatin plus paclitaxel carboplatin plus docetaxel treating patient ovarian epithelial cancer .</brief_summary>
	<brief_title>Carboplatin Plus Paclitaxel Docetaxel Treating Patients With Ovarian Epithelial Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare progression free survival chemotherapy naive patient stage IC-IV ovarian epithelial cancer follow initial surgery treat paclitaxel carboplatin versus docetaxel carboplatin . II . Compare toxic effect regimens patient . III . Determine overall survival , overall response rate , CA125 response patient regimens . IV . Determine quality life patient regimens . OUTLINE : This randomize , multicenter study . Patients stratify residual disease ( none microscopic v macroscopic great 2 cm v macroscopic great 2 cm ) , study center , FIGO stage ( IC-IV ) , performance status ( 0 vs 1 v 2 ) , tumor grade ( well-defined v moderately define v poorly defined/undifferentiated vs unknown ) , interval debulking intention ( yes v v randomize OV06 trial ) , elevate CA125 prior treatment ( yes v ) , primary peritoneal cancer ( yes v ) . Patients may undergo interval debulking surgery within 4 week third course chemotherapy , follow 6 course treatment . Patients undergo interval debulking 3 course resume chemotherapy within 3 week surgery . Patients randomize one two treatment arm . Arm I : Patients receive paclitaxel IV 3 hour , immediately follow carboplatin IV 1 hour . Arm II : Patients receive docetaxel IV 1 hour , immediately follow carboplatin IV 1 hour . Courses repeat every 21 day . Treatment continue 6 course absence disease progression unacceptable toxicity . Patients partial complete response may receive 3 additional course carboplatin alone thereafter . Quality life assess baseline , prior treatment course , every 4 month 2 year disease progression . Patients follow every 2 month 2 year , every 3 month 1 year , every 4 month 1 year , every 6 month thereafter . PROJECTED ACCRUAL : Approximately 1050 patient accrue study within 2.25 year .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage ICIV ovarian epithelial cancer IC must malignant cell ascitic fluid peritoneal washing , tumor surface ovary , preoperative capsule rupture OR Peritoneal carcinomatosis ( ovariantype ) No evidence primary fallopian tube carcinoma No mixed mesodermal tumor No borderline ovarian tumor tumor term possibly malignant PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great upper limit normal ( ULN ) OR ALT AST great 1.5 time ULN OR Alkaline phosphatase great 3 time ULN Renal : Creatinine great 1.25 time ULN Cardiovascular : No hypertension No ischemic heart disease No myocardial infarction within past 6 month No congestive heart failure Other : Not pregnant nursing Fertile patient must use effective contraception No uncontrolled infection No concurrent severe and/or uncontrolled comorbid medical condition No prior malignancy within past 5 year , except : Curatively treat carcinoma situ cervix Basal cell skin cancer No concurrent malignancy ( e.g. , endometrial cancer ) No prior serious allergic reaction ( e.g. , anaphylactic shock ) No symptomatic grade 2 great peripheral neuropathy PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : Prior surgery allow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>stage I ovarian epithelial cancer</keyword>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>